Methylphenidate
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
Methylphenidate: From ADHD to Specific Developmental Disorder
One-Sentence Summary
Methylphenidate is a central nervous system stimulant, originally used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy. The TxGNN model’s top-ranked prediction is faciodigitogenital syndrome (score 1.0000), but this has no supporting studies. The best-supported candidate in the data compiled for this report is specific developmental disorder, with 0 clinical trials and 18 publications, mostly about ADHD itself.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Attention deficit hyperactivity disorder (ADHD), narcolepsy |
| Predicted New Indication | Specific developmental disorder (rank 3; best-supported of the four candidates. The top-ranked candidate, faciodigitogenital syndrome, has no evidence.) |
| TxGNN Prediction Score | 0.9999 for specific developmental disorder (1.0000 for the top-ranked faciodigitogenital syndrome) |
| Evidence Level | L5 (preclinical/mechanistic studies and indirect literature; no trials) |
| Canada Market Status | Marketed (marketed DINs on record: at least 20) |
| Number of DINs | at least 20 |
| Recommended Decision | Hold |
All four candidates in the data:
| Rank | Predicted Indication | TxGNN Score | Evidence Level | Recommendation |
|---|---|---|---|---|
| 1 | Faciodigitogenital syndrome | 1.0000 | L5 | Hold |
| 2 | Chondromyxoid fibroma | 0.9999 | L5 | Hold |
| 3 | Specific developmental disorder | 0.9999 | L5 | Research Question |
| 4 | Dysthymic disorder | 0.9911 | L5 | Research Question |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the data compiled for this report. Based on general pharmacological knowledge, methylphenidate blocks the dopamine and norepinephrine transporters (DAT/NET), increasing these neurotransmitters in the brain. A longitudinal PET study in adults with ADHD (PMID 41128391) supports this effect on transporter binding.
Specific developmental disorder: This category is closely related to ADHD, which is already an approved use. The retrieved papers are almost entirely about ADHD, so the prediction may largely reflect a relabeling of the existing indication rather than true repurposing. No evidence was found for other specific developmental conditions, such as learning disabilities or developmental coordination disorder.
Dysthymic disorder: Dopamine and noradrenaline dysfunction is implicated in low energy and loss of pleasure, so stimulant augmentation is plausible. The available evidence only covers ADHD with accompanying mild depressive symptoms, which is indirect.
Faciodigitogenital syndrome and chondromyxoid fibroma: No mechanistic link to methylphenidate is evident. Despite very high scores, these are likely TxGNN model (deep learning) artifacts and should not be treated as evidence.
Clinical Trial Evidence
Currently no related clinical trials registered for any of the four predicted indications.
Literature Evidence
Of 18 publications retrieved for specific developmental disorder, 10 are shown here. Most concern ADHD, not other developmental disorders.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40527386 | 2025 | Cohort | Prog Neuropsychopharmacol Biol Psychiatry | Longitudinal MRI in 89 youths with ADHD and 91 controls; examines how cumulative methylphenidate exposure relates to brain structure and symptom improvement by age |
| 41128391 | 2026 | Cohort | Psychiatry Clin Neurosci | Dual-tracer PET study of extended-release methylphenidate effects on dopamine and norepinephrine transporters in adults with ADHD |
| 42819375 | 2026 | Cohort | Front Pediatr | Age-stratified FAERS pharmacovigilance analysis of ADHD medications in children (2014–2024) |
| 41655471 | 2026 | Cohort | Psychiatry Res | Meta-analysis of whether polygenic scores predict ADHD treatment response |
| 41057091 | 2025 | Preclinical | Prog Neuropsychopharmacol Biol Psychiatry | Guanfacine improved ADHD-like symptoms in a manganese-exposure model; methylphenidate previously shown effective in this model |
| 19627998 | 2009 | Review | Neuropharmacology | Neurobiology of ADHD, including frontal lobe, caudate and cerebellar differences |
| 22923783 | 2015 | Review | J Atten Disord | Methylphenidate efficacy, safety and dosing in adult versus juvenile brain |
| 22449217 | 2012 | Review | Expert Rev Neurother | Psychostimulants for ADHD-like symptoms in autism spectrum disorders (11 studies reviewed) |
| 18309764 | 2007 | Review | Nutr Health | Compares drug and nutritional approaches to ADHD; notes side effects of stimulants |
| 11563573 | 2001 | Review | Am Fam Physician | Evaluation and treatment of ADHD in school-age children |
Dysthymic disorder (3 publications):
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 24045603 | 2013 | Cohort | Clin Neuropharmacol | Methylphenidate’s effect on ADHD and mood symptoms in youths with comorbid subsyndromal depression |
| 14609500 | 2003 | Observational | Curr Psychiatry Rep | Antidepressants, amphetamine and methylphenidate may reverse negative interpersonal bias in depression and dysphoria |
| 1351794 | 1992 | Review | Clin Ther | Overview of adult ADHD |
Canada Market Information
Methylphenidate has 20 valid single-ingredient licences in Canada and none cancelled. Dosage form and approved indication text are not available in the data compiled for this report. Five main authorizations are shown:
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02247733 | CONCERTA | Not available | Not available |
| 02277131 | BIPHENTIN | Not available | Not available |
| 02553066 | JORNAY PM | Not available | Not available |
| 02470322 | FOQUEST | Not available | Not available |
| 02452731 | APO-METHYLPHENIDATE ER | Not available | Not available |
Other products include PMS-Methylphenidate CR, ACT Methylphenidate ER and Apo-Methylphenidate.
Safety Considerations
Contraindication-related conditions (from the knowledge graph, not label text):
- Cardiovascular: hypertension, coronary artery disease, myocardial infarction, stroke and cerebrovascular disorders, sudden cardiac arrest, heart conduction disease
- Psychiatric: bipolar disorder, major affective disorder, psychotic disorders, schizophreniform and schizoaffective disorders, substance abuse/dependence, anorexia nervosa
- Neurological: epilepsy
- Blood disorders: thrombocytopenia, leukopenia, anemia, hemoglobinopathy
- Other: glaucoma, hyperthyroidism, Graves disease, thyrotoxicosis
Drug Interactions (100 interactions in total; the first 20 returned are summarised):
- Major: Bupropion
- Moderate: Isometheptene, ephedrine, epinephrine, polyethylene glycol with electrolytes, picosulfuric acid, sodium sulfate
- Unknown severity: doxycycline, clotrimazole, metformin, pantoprazole, omeprazole, morphine, sucralfate, rosiglitazone, vancomycin, lactulose, triamcinolone, prednisone, simvastatin
Please refer to the package insert for official warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale:
- No clinical trials exist for any predicted indication. The two highest-scoring predictions (faciodigitogenital syndrome, chondromyxoid fibroma) have no supporting evidence or plausible mechanism, and their scores should not be treated as evidence.
- The evidence for specific developmental disorder mostly concerns ADHD, which is already an approved use, so it does not show genuinely new repurposing value. Dysthymic disorder is mechanistically plausible but supported only by indirect data. Both remain research questions rather than candidates ready for development.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism-of-action data, to allow a proper mechanistic analysis
- Clarification of which conditions fall under “specific developmental disorder” and whether they differ from the approved ADHD indication
- For dysthymic disorder: controlled trial evidence in patients with dysthymia who do not have ADHD
- A cardiovascular, psychiatric and substance-abuse risk assessment given the contraindication-related conditions and the major interaction with bupropion
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.